Clal Biotechnology Industries Ltd · TASE:CBI
Clal Biotechnology Industries — Investor Presentation (January 2023)
18 slides from Clal Biotechnology Industries's investor presentation, January 2023
Slide 1: Laser Focused on Value
LASER FOCUSED ON VALUE Corporate Presentation January 2023
Slide 2: Disclaimer
DISCLAIMER This presentation contains forward-looking statements within the meaning of the Israeli securities law that involve risks and uncertainties. These forward-looking statements relating to future events and future performance of the Company and the portfolio companies, jointly or separately,
Slide 3: The Opportunity That Comes With Experience
THE OPPORTUNITY THAT COMES WITH EXPERIENCE With over two decades of investment experience, a seasoned transatlantic leadership team and a crystalized portfolio of HealthTech companies, CBI is laser focused on value. Our seasoned team of unparalleled The value to our portfolio corporate finance, medi
Slide 4: Portfolio Holding Chart
PORTFOLIO HOLDING CHART Medical Technologies Life Sciences/ Biotechnology Other 50% 31% 25% 22% 12% 4% 12%** 7% 6% 21% 4%* 2% 2% 4 (*) CBI holds, directly, an additional 2% (**) CBI’s share in milestone payments from Novartis
Slide 5: CBI's Underlying Assets & Portfolio Holdings
CBI’S UNDERLYING ASSETS & PORTFOLIO HOLDINGS CBI Company Name Type Interest* Stage Area Solution Private (USA) 31% Phase 2 Anticoagulation Factor XIa inhibitor for thrombosis prevention - avoiding bleeding risk Private (USA) 12% Phase 1/2 Cancer Immunotherapy Unique approach to activate the immune s
Slide 6: Value Generation
VALUE GENERATION Last 5 years at a glance Nasdaq IPOs Strategic Completed 4 Collaborations Phase 3 5 3 novel drugs M&As Financing Initiated 3 Over $1 Billion Clinical trials raised 7 6
Slide 7: Multiple Pipeline Catalysts
MULTIPLE PIPELINE CATALYSTS 2022 2023 ELI-002 phase 1/2 trial initiation NexoBrid® US marketing approval Omidubicel BLA submission Frunexian phase 2 trial initiation MIJ-821 phase 2 trial readout ELI-002 phase 1/2 trial readout First ShortcutTM procedures in humans Omidubicel US marketing approval E
Slide 8: 2023
2023 8
Slide 9: Anticipating FDA Approvals in 2023
ANTICIPATING 3 FDA APPROVALS IN 2023 Clinical and regulatory progress in 2023 creates opportunity for new collaborations, potential M&As or IPOs Frunexian – end of Phase 2 EscharEX – APHEXDA start of Phase 3 FDA APPROVAL 0 FDA approvals for novel drugs 3 1 approval + 2 Anticipated FDA approvals for
Slide 10: CBI. This Is Why
New CBI. THIS IS WHY Strong Portfolio Leadership Approach Corporate Finance Orientation Data Tier-1 Driven Partners Transatlantic Focused seasoned on Value investment team Vigorous Portfolio 2023 Inflection Global Points Experience 10
Slide 11: Selected Portfolio Companies
Selected Portfolio Companies
Slide 12: Unique Approach to Activate the Immune System and Fight Cancer
UNIQUE APPROACH TO ACTIVATE THE Highlights IMMUNE SYSTEM AND FIGHT CANCER • The Amphiphile Vaccine technology is a novel Private US company in the field of immune therapy disruptive approach to unlock the therapeutic CEO- Robert Connelly; Chairman- Julian Adams; Headquarters- Boston, MA power of the
Slide 13: Factor XI Inhibitor for Thrombosis Prevention – Avoiding Bleeding Risk
FACTOR XI INHIBITOR FOR THROMBOSIS Highlights PREVENTION – AVOIDING BLEEDING RISK • Factor XIa inhibitors are a promising new class of Private US company in the field of anti-coagulation anti-coagulants CEO- Neil Hayward; Chairman- William Koster; Headquarters- Boston, MA • Frunexian is the leading,
Slide 14: Novel Tissue Repair Treatment Targeting Wound Care and Severe Burns
Novel tissue repair treatment Highlights targeting wound care and severe burns NexoBrid ® - Treatment for burns Nasdaq-traded Israeli company (Nasdaq: MDWD) • FDA Approved CEO- Ofer Gonen; Chairman- Nachum (Homi) Shamir; Headquarters- Yavne, Israel • Product Launch expected in Q2 2023 MediWound deve
Slide 15: The World Leader in Cord Blood Stem Cell Therapy
THE WORLD LEADER IN CORD BLOOD Highlights STEM CELL THERAPY Omidubicel • Offering transplant solution for Nasdaq-traded Israeli company (Nasdaq: GMDA) patients with hematological CEO- Abigail L. Jenkins; Chairman- Robert Blum; Headquarters- Boston, MA malignancies Gamida Cell is pioneering a diverse
Slide 16: CXCR4 Inhibitor for Mobilization of Hematopoietic Stem Cells
CXCR4 INHIBITOR FOR MOBILIZATION OF HEMATOPOIETIC STEM CELLS TO SUPPORT Highlights AUTOLOGOUS TRANSPLANTATION • APHEXDA is a best-in-class stem cell mobilizing treatment for autologous Private Israeli company in the field of stem cell mobilization stem cell transplantation CEO- Amnon Peled; Chairman
Slide 17: Non-Implant, Catheter-Based Solutions for Treating Heart Valves
NON-IMPLANT, CATHETER-BASED Highlights SOLUTIONS FOR TREATING HEART VALVES • World leading non-implant Private Israeli company in the field of heart valve repair heart valve repair devices CEO- Erez Golan; Chairman- Jacques R. Seguin ; Headquarters- Rehovot, Israel • Addressing high unmet medical ne
Slide 18: Now Is the Opportunity
NOW IS THE OPPORTUNITY Let’s Talk! www.cbi.co.il [email protected] in LinkedIn link Phone: +972 3 6121616 3 Azrieli Center | 132 Menachem Begin Tel Aviv, 6701101 | Israel
Clal Biotechnology Industries — Investor Presentation (January 2023) on 6ix